Skip to main content
Premium Trial:

Request an Annual Quote

Almac Teams with Queen's Univ. on Cancer PGx

NEW YORK (GenomeWeb News) – Almac today said that it is teaming up with researchers at Queen's University, Belfast to develop pharmacogenomics tests for a variety of cancers.

Almac will work with Rcihard Kennedy at the university's Centre for Cancer Research and Cell Biology in looking for stratification markers for prostate, ovarian, and breast cancer. Lab facilities and staff costs are being funded by Invest Northern Ireland and The McClay Foundation. According to Almac, Invest NI has offered the partners £1.5 million ($2.4 million) to support the collaboration.

"The research will involve using cutting-edge technology developed by Almac, which will allows us to analyze large numbers of patient tumors collected by Queen's," Kennedy said in a statement. "We will develop tests to help clinicians better understand prostate, ovarian, and breast cancer and prescribe the appropriate treatments tailored to the specific patient."

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.